Related Experiment Video
Updated: May 26, 2026
07:43
Cavernous Nerve Stimulation and Recording of Intracavernous Pressure in a Rat
Published on: April 23, 2018
Multipotent stromal cell therapy for cavernous nerve injury-induced erectile dysfunction.
Maarten Albersen1, Muammer Kendirci, Frank Van der Aa
1Laboratory of Experimental Urology, University Hospitals Leuven, Leuven, Belgium.
The Journal of Sexual Medicine
|December 8, 2011
Summary
Multipotent stromal cells (MSCs) show promise for treating erectile dysfunction (ED) after nerve injury. These cells promote recovery through paracrine signaling, offering a potential therapeutic avenue for ED.
Area of Science:
- Regenerative Medicine
- Urology
- Neuroscience
Background:
- Erectile dysfunction (ED) post-radical prostatectomy (RP) stems from cavernous nerve damage.
- Mechanisms include fibrosis and apoptosis due to nerve degeneration.
- Cell-based therapies, particularly Multipotent Stromal Cells (MSCs), are emerging for erectile function recovery.
Purpose of the Study:
- To review evidence on MSC efficacy for treating ED.
- To explore MSC mechanisms of action.
- Focus on ED following cavernous nerve injury (CNI).
Main Methods:
- Nonsystematic literature review.
- Searched English literature from 1966-2011.
- Utilized PubMed, Scopus, ScienceDirect, and Google Scholar.
Main Results:
- MSCs from bone marrow and adipose tissue demonstrated benefits in ED animal models.
- In acute CNI models, MSCs acted via paracrine signaling and cell recruitment, not differentiation.
- MSC effects varied between acute and chronic ED models.
Conclusions:
- MSCs show general efficacy in various ED animal models.
- Mechanisms of action may differ based on the disease model.
- Clinical translation requires overcoming several challenges.
